Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Rare bone disease patients tracked in Long-Term safety study

NCT ID NCT04783428

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 24 times

Summary

This study follows 23 people with tumor-induced osteomalacia (TIO), a rare condition where tumors cause weak bones. Researchers are checking how well the drug burosumab works over time and watching for side effects. Participants continue their normal treatment while the study collects health data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR-INDUCED OSTEOMALACIA (TIO) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas

    Buenos Aires, Argentina

  • Indiana University

    Bloomington, Indiana, 47405, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21218, United States

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37235, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.